Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
12.56
+1.15 (10.08%)
At close: May 12, 2025, 4:00 PM
12.80
+0.24 (1.91%)
After-hours: May 12, 2025, 5:17 PM EDT
Dyne Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Dyne Therapeutics stock have an average target of 47, with a low estimate of 17 and a high estimate of 66. The average target predicts an increase of 274.20% from the current stock price of 12.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dyne Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $46 → $38 | Strong Buy | Maintains | $46 → $38 | +202.55% | May 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +298.09% | May 9, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $18 → $17 | Hold | Maintains | $18 → $17 | +35.35% | Mar 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +266.24% | Mar 17, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +298.09% | Mar 17, 2025 |
Financial Forecast
Revenue This Year
n/a
from 773.77M
Revenue Next Year
n/a
EPS This Year
-3.64
from -3.37
EPS Next Year
-3.79
from -3.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 9.6M | 208.7M | ||
| Avg | n/a | 923,544 | 125.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 22,502.1% | ||
| Avg | - | - | 13,430.5% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.92 | -3.26 | -2.24 | ||
| Avg | -3.64 | -3.79 | -2.99 | ||
| Low | -4.28 | -4.75 | -4.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.